cd19-ucart

T Cell Lymphoma

Beijing GoBroad HospitalCell therapyPhase 1/2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the T Cell Lymphoma cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE Dizal Pharmaceuticals	Phase 3	BB
Tenalisib Rhizen Pharmaceuticals SA	Phase 1/2	B
Fostamatinib Disodium Rigel Pharmaceuticals	Phase 2	B
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Won Seog Kim	Phase 1/2	CCC
MOGAMULIZUMAB Yale University	Phase 2	CCC

View all 19 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant

BBB

Indicative ·

72 / 100

B-cell non-Hodgkin lymphomaDormant

BB

Indicative ·

71 / 100

B-cell acute lymphoblastic leukemiaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.